Table 2:

Associations of Clinical CVH Score from young age with GrimAge Acceleration

	Y15 GrimAA Measure (N=1042)						Y20 GrimAA Measure (N=957)
Exam Year of Clinical CVH Score	n	Age Range	β (95% CI)†	p	FDR	Exam Year of Clinical CVH Score	n	Age Range	β (95% CI)†	p	FDR
Prospective
Y0	1018	18–30	−0.28 (−0.47, −0.10)	0.0030	0.0039	Y0	934	18–30	−0.32 (−0.52, −0.13)	0.0014	0.0021
Y7	951	25–37	−0.28 (−0.44, −0.11)	0.00094	0.0017	Y7	871	25–37	−0.35 (−0.52, −0.18)	0.000043	0.00013
Y10	953	28–40	−0.20 (−0.35, −0.04)	0.013	0.013	Y10	884	28–40	−0.32 (−0.48, −0.17)	0.000071	0.00016
						Y15	944	33–45	−0.34 (−0.49, −0.19)	0.0000078	0.000035
Cross-sectional
Y15	1030	33–45	−0.21 (−0.36, −0.07)	0.0042	0.0047	Y20	953	38–50	−0.41 (−0.56, −0.27)	0.000000012	0.00000011

^*= Statistically significant at FDR<0.05, after adjusting for all tests presented in this table.

^†=Beta coefficient estimates represent the change in GrimAA, in years, with each point increase in CVH. P-values for each row represent a two-sided test of whether the estimate is different from zero, corresponding to the beta-value and 95% confidence interval in each row.

All models used GrimAA as the dependent variable, clinical CVH score as the independent variable, and adjusted for field center, sex, race, education, alcohol consumption, smoking status, and physical activity.

CVH components were scored as follows:

For BMI, <25 kg/m2 was ideal, 25–29.9 kg/m2 intermediate, and >30 kg/m2 poor.

For blood pressure, <120/<80 mm Hg without medications was ideal, SBP 120–139 mm Hg or DBP 80–89 mm Hg or successfully treated was intermediate, and SBP >140 or DBP >90 mm Hg poor.

For total cholesterol <200 mg/dL without medication was ideal, 200–239 mg/dL or successfully treated was intermediate, and >240 mg/dL was poor.

For fasting glucose, <100 mg/dL without medication was ideal, 100–125 mg/dL or successfully treated was intermediate, and >126 mg/dL was poor.